The tweet was deleted by the author.
But we saved everything 🙂.
MBX Biosciences has announced full 12-week results from its Avail Phase 2 trial and released new one-year open-label extension data for its once-weekly parathyroid hormone replacement candidate for adults with chronic hypoparathyroidism.
The company is inviting stakeholders to join a webcast to discuss the clinical progress. These recent findings could represent a significant development for patients seeking more effective long-term treatments for hypoparathyroidism.
MBX Biosciences recently partnered with HypoPARAassoc to advance treatment options for hypoparathyroidism in the U.S., targeting a patient population of more than 100,000 according to a previous release. The company previously highlighted precision peptide therapy developments at the Jefferies 2026 Global Healthcare Conference in New York as part of its ongoing clinical strategy. These activities reflect MBX’s continued focus on endocrine and metabolic disorders.